- Investigator
- Kethandapatti Balaji
- Status
- Accepting Candidates
- Ages
- 22 Years - 101 Years
- Sexes
- All
Treats Adults
Kethandapatti Balaji, MBBS (MD), FRCS, MRCS, LRCP
Urologist
Kethandapatti Balaji, MBBS (MD), FRCS, MRCS, LRCP
(904) 383-1016
Request appointment online
Research at a glance
Top areas of exploration
- Prostatic Neoplasms , 15 publications
- Prostate , 5 publications
- Postoperative Complications , 5 publications
- Prostatectomy , 4 publications
Research activity
Active clinical trials
My publications
Filter publications
41 publications
2023
Glomerular hyperfiltration is a predictor of adverse outcomes following major urologic oncology surgery.
International urology and nephrology
鈥�2023
Natural history, and impact of surgery and radiation on survival outcomes of men diagnosed with low-grade prostate cancer at鈥夆墹鈥�55聽years of age: a 25-year follow-up of鈥�>鈥�60,000 men.
International urology and nephrology
鈥�2022
Inter-reader reliability of the vesical imaging-reporting and data system (VI-RADS) for muscle-invasive bladder cancer: a systematic review and meta-analysis.
Abdominal radiology (New York)
鈥�2022
Complications after neoadjuvant chemotherapy and radical cystectomy for patients with bladder cancer: A propensity score matched analysis.
Canadian Urological Association journal = Journal de l'Association des urologues du Canada
鈥�2022
3JC48-3 (methyl 4鈥�-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1鈥�-biphenyl]-3-carboxylate): a novel MYC/MAX dimerization inhibitor reduces prostate cancer growth
Cancer Gene Therapy